Therefore, the treatment of HER-2-positive BC with trastuzumab and pertuzumab in the neoadjuvant setting and the first-line treatment for metastatic disease trigger ADCC activity and indirectly enhance the development of tumor-specific T cell immunity [53]. This evidence concerns the gene ERBB2 and breast cancer.